TDM-optimized Teicoplanin Dosing Versus Standard of Care
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Value of TDM for teicoplanin is not well defined. In this single-center low-interventional
randomized trial the investigators aim to investigate the superiority of teicoplanin
TDM-optimized using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus
the standard of care (dosing based on antibiotic guidelines) in target attainment.
Phase:
Phase 4
Details
Lead Sponsor:
Radboud University Medical Center
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development